ArticleJournal for immunotherapy of cancer2022
Intratumoral administration of CD1c (BDCA-1)
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03747744 (Phase I Clinical Trial on Intratumoral Injection of Autologous CD1c), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Clinical Trial on Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.Virology journal · 2023Pooled it
- Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.Nature communications · 2024Trial
- Therapeutic DC vaccination against the vascular antigen DLK1 effectively treats primary triple-negative breast cancer and prevents metastasis.NPJ vaccines · 2026Article
- Feeder-free generation of functional dendritic cells from human pluripotent stem cells.Journal for immunotherapy of cancer · 2026Article
- Review
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis.Vaccines · 2025Review
- Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cellsMolecular therapy. Oncology · 2025Article
- Review
- Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse.Nature communications · 2025Article
- Cross-priming in cancer immunology and immunotherapy.Nature reviews. Cancer · 2025Review
- Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity.Frontiers in immunology · 2025Review
- Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Dendritic cells as orchestrators of anticancer immunity and immunotherapy.Nature reviews. Clinical oncology · 2024Review
- Dendritic Cells in Cancer Immunology and Immunotherapy.Cancers · 2024Review
- Intratumoral administration of the immunologic adjuvant AS01Journal for immunotherapy of cancer · 2024Article
- Dendritic cell subsets and implications for cancer immunotherapy.Frontiers in immunology · 2024Review
- Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.Current medicinal chemistry · 2024Article
- Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)
methodsIn this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of ≥1 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)
resultsIn total, 13 patients were enrolled (cohort 1 n=2; cohort 2 n=2; cohort 3 n=3; cohort 4 n=6). Patients received a median of 6 (range 3-8) T-VEC injections. The treatment was safe with most frequent adverse events being fatigue (n=11 (85%)), fever (n=8 (62%)), and chills/influenza-like symptoms (n=6 (46%)). Nine (69%) and four patients (31%), respectively, experienced pain or redness at the injection-site. Clinical responses were documented in injected and non-injected lesions. Two patients (cohort 3) who previously progressed on anti-PD-1 therapy (and one patient also on anti-CTLA-4 therapy) developed a durable, pathologically confirmed complete response that is ongoing at 33 and 35 months following initiation of study treatment. One additional patient treated (cohort 4) had an unconfirmed partial response as best response; two additional patients had a mixed response (with durable complete responses of some injected and non-injected lesions). On-treatment biopsies revealed a strong infiltration by inflammatory cells in regressing lesions.
conclusionsIT coinjection of autologous CD1c (BDCA-1) TRIAL REGISTRATION NUMBER: NCT03747744.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.